Mixed data from two Threshold cancer trials

California-based Threshold Pharmaceuticals has released an update on its glufosfamide program. According to the company's release, a Phase II trial of the drug for soft tissue sarcoma "provided evidence of clinical activity." Threshold will continue trials of the drug for this indication, but said that dosing will have to be adjusted in later studies. The news was not so good from the ovarian cancer trial. The company has decided to drop glufosfamide due to a lack of efficacy and enrollment challenges.

In October, Threshold cut its staff and expenses after reporting disappointing data from Phase II trial of glufosfamide for small cell lung cancer. The drug is also undergoing Phase III trials for pancreatic cancer, and is in Phase I trials for the treatment of solid tumors.

- see this release from Threshold for more

Suggested Articles

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.